Outlook Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Outlook Therapeutics CEO'su Russ Trenary, Jul2021 tarihinde atandı, in görev süresi 2.75 yıldır. in toplam yıllık tazminatı $ 1.76M olup, şirket hissesi ve opsiyonları dahil olmak üzere 34.1% maaş ve 65.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.7% ine doğrudan sahiptir ve bu hisseler € 1.20M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 4.8 yıldır.

Anahtar bilgiler

Russ Trenary

İcra Kurulu Başkanı

US$1.8m

Toplam tazminat

CEO maaş yüzdesi	34.1%
CEO görev süresi	2.8yrs
CEO sahipliği	0.7%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Russ Trenary'un ücretlendirmesi Outlook Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2023	n/a	n/a	-US$51m
Sep 30 2023	US$2m	US$600k	-US$59m
Jun 30 2023	n/a	n/a	-US$60m
Mar 31 2023	n/a	n/a	-US$57m
Dec 31 2022	n/a	n/a	-US$70m
Sep 30 2022	US$1m	US$600k	-US$66m
Jun 30 2022	n/a	n/a	-US$65m
Mar 31 2022	n/a	n/a	-US$60m
Dec 31 2021	n/a	n/a	-US$53m
Sep 30 2021	US$8m	US$145k	-US$53m

Tazminat ve Piyasa: Russ 'nin toplam tazminatı ($USD 1.76M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 793.15K ).

Tazminat ve Kazançlar: Russ şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Russ Trenary (65 yo)

2.8yrs

Görev süresi

US$1,758,862

Tazminat

Mr. C. Russell Trenary, III, also known as Russ, serves as a President, Chief Executive Officer and Director at Outlook Therapeutics, Inc., since July 06, 2021. He served as the Chief Executive Officer and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ralph Thurman	Independent Executive Chairman	6yrs	US$242.50k	0.0027% € 4.5k
C. Trenary	President	2.8yrs	US$1.76m	0.70% € 1.2m
Lawrence Kenyon	Executive VP	8.6yrs	Veri yok	0.0042% € 7.3k
Jeffrey Evanson	Chief Commercial Officer	5.4yrs	US$718.20k	0.18% € 310.1k
Alicia Tozier	Senior Vice President	2.1yrs	Veri yok	Veri yok
Joel Prieve	Senior Vice President of Licensing and M&A	2.2yrs	Veri yok	Veri yok
Surendra Sharma	Senior Vice President of Medical Affairs	1.3yrs	Veri yok	Veri yok
Jennifer Kissner	Senior Vice President of Clinical Development & Regulatory Affairs	no data	Veri yok	Veri yok
Jedd Comiskey	Senior VP - Head of Europe	less than a year	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: 41ON 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ralph Thurman	Independent Executive Chairman	6yrs	US$242.50k	0.0027% € 4.5k
C. Trenary	President	2.8yrs	US$1.76m	0.70% € 1.2m
Lawrence Kenyon	Executive VP	5.7yrs	Veri yok	0.0042% € 7.3k
Kurt Hilzinger	Independent Director	8.3yrs	US$95.00k	0.11% € 181.5k
Julia Haller	Independent Director	1.7yrs	US$79.00k	0% € 0
Julian Gangolli	Independent Non-Employee Director	4yrs	US$112.50k	0% € 0
Arun Pillai	Board Observer	no data	Veri yok	Veri yok
Gerd Auffarth	Independent Non-Employee Director	4yrs	US$79.00k	0% € 0
Faisal Sukhtian	Independent Director	6.6yrs	US$113.00k	0.015% € 26.1k
Yezan Haddadin	Independent Director	6.5yrs	US$110.00k	0.023% € 38.7k
Andong Huang	Independent Director	3.8yrs	US$75.00k	0% € 0

4.8yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 41ON 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Outlook Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

Outlook Therapeutics, Inc. Announces Executive Appointments

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics, Inc. Appoints Alicia Tozier as Senior Vice President of Marketing and Market Access

Recent updates

Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

New major risk - Negative shareholders equity

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

Outlook Therapeutics, Inc. Announces Executive Appointments

Outlook Therapeutics, Inc. announced that it expects to receive $30 million in funding from Streeterville Capital, LLC

Outlook Therapeutics, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics, Inc. Confirms Status of Biologics License Application Submission for ONS-5010

Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as A Treatment for Wet AMD

Outlook Therapeutics, Inc Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Appoints Alicia Tozier as Senior Vice President of Marketing and Market Access

Independent Director recently bought €227k worth of stock

Outlook Therapeutics, Inc. Announces Appointment of Joel Prieve as Senior Vice President, Commercial Operations

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc. to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial

Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010/LYTENAVA™

Outlook Therapeutics, Inc. Reports Positive Efficacy and Safety Data from Phase 3 NORSE TWO Trial of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

Forecast to breakeven in 2023

Outlook Therapeutics, Inc. Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial

Forecast breakeven pushed back to 2024

Outlook Therapeutics, Inc. Provides Update on the Clinical Progress of ONS-5010 (Bevacizumab-Vikg) in Virtual Clinical Day

Outlook Therapeutics, Inc., Annual General Meeting, Mar 24, 2021

Chief Operating Officer recently sold €134k worth of stock

Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA™

Outlook Therapeutics, Inc. Recent Financing Secures Funding to Support Ons-5010 / Lytenava™ Through Planne Bla Submission

New 90-day high: €1.39

New 90-day high: €1.07

Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

New 90-day high: €1.04

Outlook Therapeutics, Inc. Announces Board Appointments

Outlook Therapeutics, Inc. announced that it has received $10 million in funding

Outlook Therapeutics, Inc. Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-Vikg for Advanced Macular Degeneration

New 90-day low - €0.58

Earnings released

Outlook Therapeutics, Inc. announced that it has received $1 million in funding from Syntone Ventures LLC

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi